Cargando…
An update on the anxiolytic and neuroprotective properties of etifoxine: from brain GABA modulation to a whole-body mode of action
Treating the signs and symptoms of anxiety is an everyday challenge in clinical practice. When choosing between treatment options, anxiety needs to be understood in the situational, psychiatric, and biological context in which it arises. Etifoxine, a non-benzodiazepine anxiolytic drug belonging to t...
Autores principales: | Nuss, Philippe, Ferreri, Florian, Bourin, Michel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615018/ https://www.ncbi.nlm.nih.gov/pubmed/31308671 http://dx.doi.org/10.2147/NDT.S200568 |
Ejemplares similares
-
The Non-Benzodiazepine Anxiolytic Drug Etifoxine Causes a Rapid, Receptor-Independent Stimulation of Neurosteroid Biosynthesis
por: do Rego, Jean Luc, et al.
Publicado: (2015) -
Etifoxine for Pain Patients with Anxiety
por: Choi, Yun Mi, et al.
Publicado: (2015) -
Animal models for screening anxiolytic-like drugs: a perspective
por: Bourin, Michel
Publicado: (2015) -
The non-benzodiazepine anxiolytic etifoxine limits mechanical allodynia and anxiety-like symptoms in a mouse model of streptozotocin-induced diabetic neuropathy
por: Gazzo, Géraldine, et al.
Publicado: (2021) -
Reduction of Traumatic Brain Damage by Tspo Ligand Etifoxine
por: Shehadeh, Mona, et al.
Publicado: (2019)